Abstract:Background Disease-modifying treatments are in development for Huntington's disease; crucial to their success is to identify a timepoint in a patient's life when there is a measurable biomarker of early neurodegeneration while clinical function is still intact. We aimed to identify this timepoint in a novel cohort of young adult premanifest Huntington's disease gene carriers (preHD) far from predicted clinical symptom onset. Methods We did the Huntington's disease Young Adult Study (HD-YAS) in the UK. We recruited young adults with preHD and controls matched for age, education, and sex to ensure each group had at least 60 participants with imaging data, accounting for scan fails. Controls either had a family history of Huntington's disease but a negative genetic test, or no known family history of Huntington's disease. All participants underwent detailed neuropsychiatric and cognitive assessments, including tests from the Cambridge Neuropsychological Test Automated Battery and a battery assessing emotion, motivation, impulsivity and social cognition (EMOTICOM). Imaging (done for all participants without contraindications) included volumetric MRI, diffusion imaging, and multiparametric mapping. Biofluid markers of neuronal health were examined using blood and CSF collection. We did a cross-sectional analysis using general least-squares linear models to assess group differences and associations with age and CAG length, relating to predicted years to clinical onset. Results were corrected for multiple comparisons using the false discovery rate (FDR), with FDR <0.05 deemed a significant result. Findings Data were obtained between Aug 2, 2017, and April 25, 2019. We recruited 64 young adults with preHD and 67 controls. Mean ages of participants were 29.0 years (SD 5.6) and 29.1 years (5.7) in the preHD and control groups, respectively. We noted no significant evidence of cognitive or psychiatric impairment in preHD participants 23.6 years (SD 5.8) from predicted onset (FDR 0.22-0.87 for cognitive measures, 0.31-0.91 for neuropsychiatric measures). The preHD cohort had slightly smaller putamen volumes (FDR=0.03), but this did not appear to be closely related to predicted years to onset (FDR=0.54). There were no group differences in other brain imaging measures (FDR >0.16). CSF neurofilament light protein (NfL), plasma NfL, and CSF YKL-40 were elevated in this far-from-onset preHD cohort compared with controls (FDR<0.0001, =0.01, and =0.03, respectively). CSF NfL elevations were more likely in individuals closer to expected clinical onset (FDR <0.0001). Interpretation We report normal brain function yet a rise in sensitive measures of neurodegeneration in a preHD cohort approximately 24 years from predicted clinical onset. CSF NfL appears to be a more sensitive measure than plasma NfL to monitor disease progression. This preHD cohort is one of the earliest yet studied, and our findings could be used to inform decisions about when to initiate a potential future intervention to delay or prevent further neurodegeneration while function is intact.

Characterizing differences in retinal and choroidal microvasculature and structure in individuals with Huntington's Disease compared to healthy controls: A cross-sectional prospective study

Is retina affected in Huntington's disease? Is optical coherence tomography a good biomarker?

Optical coherence tomography measurements in Huntington's disease: a systematic review and meta-analysis

Striatal morphology and neurocognitive dysfunction in Huntington disease: The IMAGE-HD study

Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy

Altered Iron and Microstructure in Huntington's Disease Subcortical Nuclei: Insight From 7T MRI

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD

Microglial proliferation and astrocytic protein alterations in the human Huntington's disease cortex

Abnormal Outer and Inner Retina in a Mouse Model of Huntington’s Disease with Age

Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review

Huntington disease: natural history, biomarkers and prospects for therapeutics

Neurovascular abnormalities in humans and mice with Huntington's disease.

Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease

F05 Biological and Clinical Characteristics of Gene Carriers Far from Predicted Onset in the Hd-Yas Study: a Cross-Sectional Analysis

Reflexive and voluntary saccadic eye movements as biomarker of Huntington's Disease

Genetic Load Determines Atrophy in Hand Cortico-Striatal Pathways in Presymptomatic Huntington's Disease

Identification of the Transcriptional Biomarkers Panel Linked to Pathological Remodelling of the Eye Tissues in Various HD Mouse Models

White Matter Microstructure Changes Revealed by Diffusion Kurtosis and Diffusion Tensor Imaging in Mutant Huntingtin Gene Carriers

Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington’s Disease

High levels of mutant huntingtin protein in tear fluid from Huntington’s Disease Gene Expansion Carriers